GILEAD SCIENCES, INC. Payments to Acquire Available-for-sale Securities
GILEAD SCIENCES, INC. (GILD) reported Payments to Acquire Available-for-sale Securities of $19.81 billion for the 9-month period ending 2020-09-30, per its 10-Q filed 2020-11-04.
Discontinued › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireAvailableForSaleSecurities · last filed 2020-11-04
- GILEAD SCIENCES, INC. payments to acquire available-for-sale securities for the quarter ending 2020-09-30 was $3.06B, a 56.56% decline year-over-year.
- GILEAD SCIENCES, INC. payments to acquire available-for-sale securities for the quarter ending 2020-06-30 was $3.60B, a 65.10% decline year-over-year.
- GILEAD SCIENCES, INC. payments to acquire available-for-sale securities for the quarter ending 2020-03-31 was $13.16B, a 95.75% increase year-over-year.
- GILEAD SCIENCES, INC. payments to acquire available-for-sale securities for the quarter ending 2019-09-30 was $7.04B, a 86.26% increase year-over-year.
- GILEAD SCIENCES, INC. payments to acquire available-for-sale securities for fiscal 2017 was $23.31B, a 9.00% decline from fiscal 2016.
- GILEAD SCIENCES, INC. payments to acquire available-for-sale securities for fiscal 2016 was $25.62B, a 48.61% increase from fiscal 2015.
- GILEAD SCIENCES, INC. payments to acquire available-for-sale securities for fiscal 2015 was $17.24B, a 718.18% increase from fiscal 2014.
- GILEAD SCIENCES, INC. payments to acquire available-for-sale securities for fiscal 2014 was $2.11B, a 719.84% increase from fiscal 2013.
| Period end | Payments to Acquire Available-for-sale Securities 3 month | Payments to Acquire Available-for-sale Securities 3 month as first filed | Payments to Acquire Available-for-sale Securities 6 month | Payments to Acquire Available-for-sale Securities 6 month as first filed | Payments to Acquire Available-for-sale Securities 9 month | Payments to Acquire Available-for-sale Securities 9 month as first filed | Payments to Acquire Available-for-sale Securities 12 month | Payments to Acquire Available-for-sale Securities 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2020-09-30 | $3.06B derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-04 | $6.65B derived: sum of 2 quarters · filed 2020-11-04 | $19.81B 10-Q · filed 2020-11-04 | |||||
| 2020-06-30 | $3.60B derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-06 | $16.75B 10-Q · filed 2020-08-06 | ||||||
| 2020-03-31 | $13.16B 10-Q · filed 2020-05-06 | |||||||
| 2019-09-30 | $7.04B derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-04 | $17.34B derived: sum of 2 quarters · filed 2020-11-04 | $24.06B 10-Q · filed 2020-11-04 | |||||
| 2019-06-30 | $10.30B derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-06 | $17.02B 10-Q · filed 2020-08-06 | ||||||
| 2019-03-31 | $6.72B 10-Q · filed 2020-05-06 | |||||||
| 2018-09-30 | $3.78B derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-05 | $5.39B derived: sum of 2 quarters · filed 2019-11-05 | $5.79B 10-Q · filed 2019-11-05 | $10.29B derived: sum of 4 quarters · filed 2019-11-05 | ||||
| 2018-06-30 | $1.61B derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-06 | $2.01B 10-Q · filed 2019-08-06 | $6.51B derived: sum of 3 quarters · filed 2019-08-06 | $12.05B derived: sum of 4 quarters · filed 2019-08-06 | ||||
| 2018-03-31 | $397.00M 10-Q · filed 2019-05-08 | $4.90B derived: sum of 2 quarters · filed 2019-05-08 | $10.44B derived: sum of 3 quarters · filed 2019-05-08 | $20.23B derived: sum of 4 quarters · filed 2019-05-08 | ||||
| 2017-12-31 | $4.50B derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-27 | $10.04B derived: sum of 2 quarters · filed 2018-11-06 | $19.83B derived: sum of 3 quarters · filed 2018-11-06 | $23.31B 10-K · filed 2018-02-27 | ||||
| 2017-09-30 | $5.54B derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-06 | $15.33B derived: sum of 2 quarters · filed 2018-11-06 | $18.81B 10-Q · filed 2018-11-06 | $24.55B derived: sum of 4 quarters · filed 2018-11-06 | ||||
| 2017-06-30 | $9.79B derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-06 | $13.27B 10-Q · filed 2018-08-06 | $19.01B derived: sum of 3 quarters · filed 2018-08-06 | $26.87B derived: sum of 4 quarters · filed 2018-08-06 | ||||
| 2017-03-31 | $3.48B 10-Q · filed 2018-05-09 | $9.22B derived: sum of 2 quarters · filed 2018-05-09 | $17.08B derived: sum of 3 quarters · filed 2018-05-09 | $24.12B derived: sum of 4 quarters · filed 2018-05-09 | ||||
| 2016-12-31 | $5.74B derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-27 | $13.60B derived: sum of 2 quarters · filed 2018-02-27 | $20.64B derived: sum of 3 quarters · filed 2018-02-27 | $25.62B 10-K · filed 2018-02-27 | ||||
| 2016-09-30 | $7.86B derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-07 | $14.90B derived: sum of 2 quarters · filed 2017-11-07 | $19.88B 10-Q · filed 2017-11-07 | $24.83B derived: sum of 4 quarters · filed 2018-02-27 | ||||
| 2016-06-30 | $7.04B derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-07 | $12.02B 10-Q · filed 2017-08-07 | $16.97B derived: sum of 3 quarters · filed 2018-02-27 | $22.41B derived: sum of 4 quarters · filed 2018-02-27 | ||||
| 2016-03-31 | $4.98B 10-Q · filed 2017-05-10 | $9.93B derived: sum of 2 quarters · filed 2018-02-27 | $15.37B derived: sum of 3 quarters · filed 2018-02-27 | $19.75B derived: sum of 4 quarters · filed 2018-02-27 | ||||
| 2015-12-31 | $4.95B derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-27 | $10.39B derived: sum of 2 quarters · filed 2018-02-27 | $14.78B derived: sum of 3 quarters · filed 2018-02-27 | $17.24B 10-K · filed 2018-02-27 | ||||
| 2015-09-30 | $5.44B derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-07 | $9.83B derived: sum of 2 quarters · filed 2016-11-07 | $12.29B 10-Q · filed 2016-11-07 | $12.87B derived: sum of 4 quarters · filed 2017-02-27 | ||||
| 2015-06-30 | $4.38B derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-05 | $6.85B 10-Q · filed 2016-08-05 | $7.42B derived: sum of 3 quarters · filed 2017-02-27 | $8.30B derived: sum of 4 quarters · filed 2017-02-27 | ||||
| 2015-03-31 | $2.46B 10-Q · filed 2016-05-06 | $3.04B derived: sum of 2 quarters · filed 2017-02-27 | $3.92B derived: sum of 3 quarters · filed 2017-02-27 | $4.47B derived: sum of 4 quarters · filed 2017-02-27 | ||||
| 2014-12-31 | $575.00M derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-27 | $1.46B derived: sum of 2 quarters · filed 2017-02-27 | $2.01B derived: sum of 3 quarters · filed 2017-02-27 | $2.11B 10-K · filed 2017-02-27 | ||||
| 2014-09-30 | $882.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-04 | $1.44B derived: sum of 2 quarters · filed 2015-11-04 | $1.53B 10-Q · filed 2015-11-04 | $1.53B 10-Q · filed 2014-11-05 | $1.53B derived: sum of 4 quarters · filed 2016-02-24 | |||
| 2014-06-30 | $556.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-05 | $650.00M 10-Q · filed 2015-08-05 | $650.15M 10-Q · filed 2014-08-04 | $652.34M derived: sum of 3 quarters · filed 2016-02-24 | $707.64M derived: sum of 4 quarters · filed 2016-02-24 | |||
| 2014-03-31 | $94.00M 10-Q · filed 2015-05-08 | $94.34M 10-Q · filed 2014-05-07 | $96.34M derived: sum of 2 quarters · filed 2016-02-24 | $151.64M derived: sum of 3 quarters · filed 2016-02-24 | $288.40M derived: sum of 4 quarters · filed 2016-02-24 | |||
| 2013-12-31 | $2.34M derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-24 | $57.64M derived: sum of 2 quarters · filed 2016-02-24 | $194.40M derived: sum of 3 quarters · filed 2016-02-24 | $257.00M 10-K · filed 2016-02-24 | $256.70M 10-K · filed 2014-02-25 | |||
| 2013-09-30 | $55.30M derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-05 | $192.05M derived: sum of 2 quarters · filed 2014-11-05 | $254.66M 10-Q · filed 2014-11-05 | $350.91M derived: sum of 4 quarters · filed 2015-02-25 | ||||
| 2013-06-30 | $136.75M derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-04 | $199.36M 10-Q · filed 2014-08-04 | $295.61M derived: sum of 3 quarters · filed 2015-02-25 | $837.28M derived: sum of 4 quarters · filed 2015-02-25 | ||||
| 2013-03-31 | $62.60M 10-Q · filed 2014-05-07 | $158.85M derived: sum of 2 quarters · filed 2015-02-25 | $700.53M derived: sum of 3 quarters · filed 2015-02-25 | $1.31B derived: sum of 4 quarters · filed 2015-02-25 | ||||
| 2012-12-31 | $96.25M derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-25 | $637.92M derived: sum of 2 quarters · filed 2015-02-25 | $1.25B derived: sum of 3 quarters · filed 2015-02-25 | $1.25B 10-K · filed 2015-02-25 | $1.24B 10-K · filed 2013-02-27 | |||
| 2012-09-30 | $541.67M derived: 10-Q 9 month − 10-Q 6 month · filed 2013-10-31 | $1.15B derived: sum of 2 quarters · filed 2013-10-31 | $1.15B 10-Q · filed 2013-10-31 | $2.12B derived: sum of 4 quarters · filed 2014-02-25 | ||||
| 2012-06-30 | $607.08M derived: 10-Q 6 month − 10-Q 3 month · filed 2013-08-01 | $607.08M 10-Q · filed 2013-08-01 | $1.57B derived: sum of 3 quarters · filed 2014-02-25 | $3.02B derived: sum of 4 quarters · filed 2014-02-25 | ||||
| 2012-03-31 | $0.00 10-Q · filed 2013-05-08 | $966.47M derived: sum of 2 quarters · filed 2014-02-25 | $2.41B derived: sum of 3 quarters · filed 2014-02-25 | $3.61B derived: sum of 4 quarters · filed 2014-02-25 | ||||
| 2011-12-31 | $966.47M derived: 10-K 12 month − 10-Q 9 month · filed 2014-02-25 | $2.41B derived: sum of 2 quarters · filed 2014-02-25 | $3.61B derived: sum of 3 quarters · filed 2014-02-25 | $5.13B 10-K · filed 2014-02-25 | ||||
| 2011-09-30 | $1.45B derived: 10-Q 9 month − 10-Q 6 month · filed 2012-11-06 | $2.64B derived: sum of 2 quarters · filed 2012-11-06 | $4.16B 10-Q · filed 2012-11-06 | $5.86B derived: sum of 4 quarters · filed 2013-02-27 | ||||
| 2011-06-30 | $1.19B derived: 10-Q 6 month − 10-Q 3 month · filed 2012-08-01 | $2.71B 10-Q · filed 2012-08-01 | $4.42B derived: sum of 3 quarters · filed 2013-02-27 | $6.20B derived: sum of 4 quarters · filed 2013-02-27 | ||||
| 2011-03-31 | $1.52B 10-Q · filed 2012-05-04 | $3.22B derived: sum of 2 quarters · filed 2013-02-27 | $5.01B derived: sum of 3 quarters · filed 2013-02-27 | $5.52B derived: sum of 4 quarters · filed 2013-02-27 | ||||
| 2010-12-31 | $1.70B derived: 10-K 12 month − 10-Q 9 month · filed 2013-02-27 | $3.49B derived: sum of 2 quarters · filed 2013-02-27 | $4.00B derived: sum of 3 quarters · filed 2013-02-27 | $5.50B 10-K · filed 2013-02-27 | ||||
| 2010-09-30 | $1.78B derived: 10-Q 9 month − 10-Q 6 month · filed 2011-11-04 | $2.30B derived: sum of 2 quarters · filed 2011-11-04 | $3.80B 10-Q · filed 2011-11-04 | $4.50B derived: sum of 4 quarters · filed 2012-02-23 | ||||
| 2010-06-30 | $513.38M derived: 10-Q 6 month − 10-Q 3 month · filed 2011-08-05 | $2.02B 10-Q · filed 2011-08-05 | $2.71B derived: sum of 3 quarters · filed 2012-02-23 | $3.44B derived: sum of 4 quarters · filed 2012-02-23 | ||||
| 2010-03-31 | $1.50B 10-Q · filed 2011-05-09 | $2.20B derived: sum of 2 quarters · filed 2012-02-23 | $2.93B derived: sum of 3 quarters · filed 2012-02-23 | $3.24B derived: sum of 4 quarters · filed 2012-02-23 | ||||
| 2009-12-31 | $697.55M derived: 10-K 12 month − 10-Q 9 month · filed 2012-02-23 | $1.42B derived: sum of 2 quarters · filed 2012-02-23 | $1.73B derived: sum of 3 quarters · filed 2012-02-23 | $2.61B 10-K · filed 2012-02-23 | ||||
| 2009-09-30 | $726.22M derived: 10-Q 9 month − 10-Q 6 month · filed 2010-11-08 | $1.04B derived: sum of 2 quarters · filed 2010-11-08 | $1.92B 10-Q · filed 2010-11-08 | $2.94B derived: sum of 4 quarters · filed 2011-02-28 | ||||
| 2009-06-30 | $310.84M derived: 10-Q 6 month − 10-Q 3 month · filed 2010-08-09 | $1.19B 10-Q · filed 2010-08-09 | $2.21B derived: sum of 3 quarters · filed 2011-02-28 | $3.16B derived: sum of 4 quarters · filed 2011-02-28 | ||||
| 2009-03-31 | $879.44M 10-Q · filed 2010-05-10 | $1.90B derived: sum of 2 quarters · filed 2011-02-28 | $2.84B derived: sum of 3 quarters · filed 2011-02-28 | |||||
| 2008-12-31 | $1.02B derived: 10-K 12 month − 10-Q 9 month · filed 2011-02-28 | $1.97B derived: sum of 2 quarters · filed 2011-02-28 | $3.27B 10-K · filed 2011-02-28 | |||||
| 2008-09-30 | $943.65M derived: 10-Q 9 month − 10-Q 6 month · filed 2009-11-05 | $2.25B 10-Q · filed 2009-11-05 | ||||||
| 2008-06-30 | $1.31B 10-Q · filed 2009-08-05 | |||||||
| 2007-12-31 | $3.50B 10-K · filed 2010-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AMGEN INC (AMGN) | United States | $219.567B | 22.39 |
| Moderna, Inc. (MRNA) | United States | $77.819B | -8.86 |
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| BIOGEN INC. (BIIB) | United States | $33.427B | 19.60 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |